

Company No. 12615561

GSK FINANCE (NO.3) LIMITED

DIRECTORS' STATEMENT FOR THE PURPOSES OF SECTION 644(5) OF THE
COMPANIES ACT 2006

On 20 March 2024, GSK Finance (No.3) Limited (the "Company") passed a special resolution to reduce its share capital (the "Special Resolution"). The Special Resolution was supported by a solvency statement made by the directors of the Company on 20 March 2024 (the "Solvency Statement").


We, being all of the directors of the Company, confirm, for the purposes of section 644(5) of the Companies Act 2006, that:

1. the Solvency Statement was made not more than 15 days before the date on which the Special Resolution was passed; and
2. a copy of the Solvency Statement was provided to members in accordance with section 642(2) of the Companies Act 2006.

Signed by each of the directors on 21 March 2024.




Peter Hopkins



Alistair Davidson



Darren Barnett,
Authorised Signatory
Representing The Wellcome Foundation Limited
Corporate Director



Marcus Dowding
Authorised Signatory
Representing Edinburgh Pharmaceutical Industries Limited
Corporate Director